"Prognosis" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A prediction of the probable outcome of a disease based on a individual's condition and the usual course of the disease as seen in similar situations.
| Descriptor ID |
D011379
|
| MeSH Number(s) |
E01.789
|
| Concept/Terms |
Prognostic Factors- Prognostic Factors
- Factor, Prognostic
- Factors, Prognostic
- Prognostic Factor
|
Below are MeSH descriptors whose meaning is more general than "Prognosis".
- Analytical, Diagnostic and Therapeutic Techniques and Equipment [E]
- Diagnosis [E01]
- Prognosis [E01.789]
Below are MeSH descriptors whose meaning is more specific than "Prognosis".
This graph shows the total number of publications written about "Prognosis" by people in this website by year, and whether "Prognosis" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 0 | 21 | 21 |
| 1996 | 0 | 26 | 26 |
| 1997 | 0 | 22 | 22 |
| 1998 | 0 | 30 | 30 |
| 1999 | 0 | 35 | 35 |
| 2000 | 0 | 53 | 53 |
| 2001 | 0 | 31 | 31 |
| 2002 | 0 | 26 | 26 |
| 2003 | 1 | 51 | 52 |
| 2004 | 0 | 55 | 55 |
| 2005 | 0 | 63 | 63 |
| 2006 | 0 | 46 | 46 |
| 2007 | 0 | 73 | 73 |
| 2008 | 1 | 87 | 88 |
| 2009 | 1 | 86 | 87 |
| 2010 | 0 | 89 | 89 |
| 2011 | 0 | 121 | 121 |
| 2012 | 0 | 123 | 123 |
| 2013 | 0 | 140 | 140 |
| 2014 | 1 | 119 | 120 |
| 2015 | 1 | 143 | 144 |
| 2016 | 1 | 130 | 131 |
| 2017 | 2 | 136 | 138 |
| 2018 | 4 | 139 | 143 |
| 2019 | 1 | 165 | 166 |
| 2020 | 1 | 142 | 143 |
| 2021 | 1 | 103 | 104 |
| 2022 | 0 | 47 | 47 |
| 2023 | 0 | 54 | 54 |
| 2024 | 0 | 88 | 88 |
| 2025 | 0 | 16 | 16 |
To return to the timeline,
click here.
Below are the most recent publications written about "Prognosis" by people in Profiles.
-
Hepatosplenic T-cell lymphoma in children and adolescents. Blood Adv. 2025 Apr 22; 9(8):1847-1858.
-
The Effect of Etrasimod on Fecal Calprotectin and High-sensitivity C-reactive Protein: Results From the ELEVATE UC Clinical Program. Inflamm Bowel Dis. 2025 Apr 10; 31(4):923-934.
-
Clinical use of measurable residual disease in adult ALL: recommendations from a panel of US experts. Blood Adv. 2025 Mar 25; 9(6):1442-1451.
-
Peripheral T-cell lymphoma-NOS in children and adolescents: a review from the Children's Oncology Group NHL Committee. Blood Adv. 2025 Mar 25; 9(6):1420-1431.
-
Insights from autopsy-initiated pathological studies of the pathogenesis and clinical manifestations of atherosclerosis and ischemic heart disease: Part I. Atherosclerosis. Cardiovasc Pathol. 2025 May-Jun; 76:107726.
-
Insights from autopsy-initiated pathological studies of the pathogenesis and clinical manifestations of atherosclerosis and ischemic heart disease: Part II. Ischemic heart disease. Cardiovasc Pathol. 2025 May-Jun; 76:107727.
-
Survey of Extracorporeal Life Support Application in Lung Transplantation. Clin Transplant. 2025 Feb; 39(2):e70094.
-
Preoperative Chest CT Myosteatosis Indicates Worse Postoperative Survival in Stage 0-IIB Non-Small Cell Lung Cancer. Radiology. 2025 Feb; 314(2):e240282.
-
TP53 Mutations in Myeloproliferative Neoplasms: Context-Dependent Evaluation of Prognostic Relevance. Am J Hematol. 2025 Apr; 100(4):552-560.
-
Hormone Receptor-Positive HER2-Negative/MammaPrint High-2 Breast Cancers Closely Resemble Triple-Negative Breast Cancers. Clin Cancer Res. 2025 Jan 17; 31(2):403-413.